Pneumonia News and Research

Latest Pneumonia News and Research

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

A popular stomach-acid reducer used to prevent stress ulcers in critically ill patients needing breathing machine support increases the risk of those patients contracting pneumonia threefold, according to researchers at Wake Forest University School of Medicine.

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

Boston University launches $10M, 5-year Global Health Center

Boston University (BU) on Monday launched a five-year, $10 million global health initiative that aims to "bolster research and education" and "build a nationwide consortium of universities devoted to improving health in the Third World," the Boston Globe reports.

14 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

Final results of SAPHRIS clinical study released

Schering-Plough Corporation today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

Prevention and treatment of pneumonia are critical to reducing child mortality

New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.

14 Sep 2009

FOCUS 1 and FOCUS 2 clinical trial results released

Forest Laboratories, Inc today presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III studies of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients.

14 Sep 2009

Pneumonia-causing diseases kill 1.2m children under 5 annually, Studies say

"Each year 1.2 million children under age 5 die from Streptococcus pneumoniae and Haemophilus influenzae B or Hib," which cause pneumococcal disease and are preventable with vaccines, according to studies published Thursday in the journal Lancet, Reuters reports.

11 Sep 2009

HHS Secretary to issue new report on the employer-sponsored insurance market

HHS Secretary Kathleen Sebelius today will address the University of Chicago’s dialogue on health care reform and education and issue a new report on the employer-sponsored insurance market.

11 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

New World Health Organization data emphasizes on two leading causes of pneumonia

New World Health Organization data to be published in this week's edition of The Lancet will shed new light on two leading causes of pneumonia, the world’s leading killer of children under age 5, both globally and within specific countries.

11 Sep 2009

Under-five mortality rate continues to decline

UNICEF today released new figures that show the rate of deaths of children under five years of age continued to decline in 2008.

11 Sep 2009

Better use of quality-of-care ratings can lead to greater consumer control

A hospital pneumonia survival rate of 93 percent may sound good, but knowing that it's actually merely "fair" can help people pick a better hospital, according to new research. A "good" survival rate would be from 95 percent to 98 percent, medical experts say.

11 Sep 2009

UNICEF data shows global child mortality now below 9m, progress not enough to achieve MDG in most regions

The annual number of deaths among children younger than five worldwide "has fallen below nine million" compared with 12.5 million in 1990, according to new data from UNICEF, the New York Times reports. "That's 10,000 less children dying per day," Ann Veneman, UNICEF's executive director, said.

10 Sep 2009

U.S. public health officials recommend early flu vaccination

With increased influenza activity anticipated this fall, U.S. public health officials and other leading medical experts today urged Americans to be vigilant and get immunized early for protection against seasonal influenza - a threat to Americans' health each and every year.

10 Sep 2009